ClinicalTrials.gg
CompletedNCT07393022Updated Feb 6, 2026

Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects

A Phase 1 interventional study of Levetiracetam 1500 mg and Keppra® 750 mg in Pharmacokinetic Analysis, Bioequivalence and Health Adult Subjects, sponsored by Desitin Arzneimittel GmbH. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Desitin Arzneimittel GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Pivotal, single-dose, randomized, open-label, two-period, two-sequence, two-treatment, single-centre, crossover, bioequivalence study of Levetiracetam 1500 mg coated granules in sachet formulations and Keppra (Levetiracetam) 2 x 750 mg film-coated tablet formulations in healthy male and female under fasting conditions.

Read the detailed description

This will be a pivotal, single-dose, randomized, open-label, two-period, two-sequence, two-treatment, single-centre, crossover, bioequivalence study of Levetiracetam 1500 mg coated granules in sachet formulations and Keppra (Levetiracetam) 2 x 750 mg film-coated tablet formulations in healthy, non-smoking, male and non-pregnant, non-lactating female. The products will be studied using a crossover design with 20 healthy, non-smoking, male and non-pregnant, non-lactating female volunteers being administered an oral dose of 1 × 1500 mg coated granules in sachet (Test Drug A) or 2 x 750 mg film-coated tablets (Reference Drug B) under fasting conditions.

02

Conditions studied

  • Pharmacokinetic Analysis
  • Bioequivalence
  • Health Adult Subjects

Keywords

  • single dose
  • randomized
  • bioequivalence
  • two-period
  • crossover
  • levetiracetam
03

In context

Lead sponsor

Desitin Arzneimittel GmbH is the lead sponsor of 13 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, non-smoking (for at least 6 months prior to first drug administration) male and non-pregnant female volunteers, 18 years of age and older, inclusive.
  2. that is between 18.5-30.0 kg/m², inclusive.
  3. Healthy, according to the medical history, , vital signs, laboratory results and physical examination as determined by the PI/Sub-Investigator.
  4. ≤ 450 milliseconds for males and ≤ 470 milliseconds for females, unless deemed otherwise by the PI/Sub-Investigator.
  5. Systolic blood pressure between 95-140 mmHg, inclusive, and diastolic blood pressure between 55-90 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless deemed otherwise by the PI/Sub-Investigator.
  6. Clinical laboratory values within BPSI's most recent acceptable laboratory test range, and/or values are deemed by the PI/Sub-Investigator as "Not ".
  7. Ability to comprehend and be informed of the nature of the study, as assessed by BPSI staff. Capable of giving written prior to any study- related procedure. Must be able to communicate effectively with clinic staff.
  8. Ability to fast for at least 14 hours and consume standard meals.
  9. Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements.
  10. Agree not to have a tattoo or body piercing until the end of the study.
  11. Agree not to drive or operate heavy machinery if feeling dizzy or drowsy following study drug administration until full mental alertness is regained.
  12. Female participants must fulfill at least one of the following:

    • Be surgically sterile for a minimum of 6 months (achieved through partial or total hysterectomy, bilateral oophorectomy, bilateral tubal ligation or bilateral salpingectomy); BPSI Protocol Number: 2953 Sponsor Protocol Number: LEV-004/K Protocol Version Number: 1.0, Dated: Oct-14-2025 Levetiracetam 1500 mg coated granules in sachet formulations Fasting Conditions Page 19 of 51
    • for a minimum of 1 year (postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause), confirmed by FSH test;
    • Agree to avoid pregnancy and use medically acceptable method of from at least 30 days prior to the study until 30 days after the study has ended (last study procedure).

Exclusion criteria

Exclusion Criteria:

  1. Known history or presence of any hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the PI/Sub-Investigator.
  2. Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug experienced within 7 days prior to first study drug administration, as determined by the PI/Sub-Investigator.
  3. Estimated \<60 ml/min, unless determined as not clinically significant by the PI/Sub-Investigator.
  4. Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the PI/Sub-Investigator.
  5. Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator.
  6. A positive test result for any of the following: , surface antigen, , drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), breath alcohol test and cotinine. Positive pregnancy test for female participants.
  7. Known history or presence of:

    • Alcohol abuse or dependence within one year prior to first study drug administration;
    • Drug abuse or dependence;
    • Significant reaction (allergic, anaphylactic, , angioedema) or severe response to levetiracetam, their and to any other drug or food unless deemed by the PI/Sub-I as "Not Clinically Significant.";
    • Stevens-Johnson syndrome (SJS);
    • Toxic Epidermal Necrolysis (TEN);
    • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS);
    • Seizure associated with a particular genetic mutation called SCN8A mutation; BPSI Protocol Number: 2953 Sponsor Protocol Number: LEV-004/K Protocol Version Number: 1.0, Dated: Oct-14-2025 Levetiracetam 1500 mg coated granules in sachet formulations Fasting Conditions Page 21 of 51

    Suicidal ideation, attempts and/or behaviour, as assessed by the C-SSRS (baseline version) - Appendix B;

    • Presence of any dietary restrictions unless deemed by the PI/Sub-I as "Not Clinically Significant".
  8. Intolerance to and/or difficulty with blood sampling through venipuncture.
  9. Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets etc.
  10. Individuals who have donated, in the days prior to first study drug administration:

    • 50-499 mL of blood in the previous 30 days;
    • 500 mL of blood or more in the previous 56 days.
  11. Donation of plasma by plasmapheresis within 7 days prior to first study drug administration.
  12. Individuals who have participated in another clinical trial or who received an drug within 30 days prior to first study drug administration.
  13. Use of any prescription medication within 14 days prior to first study drug administration (except for medically acceptable products).
  14. Use of any over-the-counter medications (including oral multivitamins, herbal and/or dietary supplements) within 14 days prior to first study drug administration (except for medically acceptable contraceptive products).
  15. Consumption of food or beverages containing grapefruit and/or pomelo within 10 days prior to first study drug administration.
  16. Consumption of food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing in each study period.
  17. Individuals having undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by PI/Sub-Investigator.
  18. Difficulty with swallowing whole tablets or granules.
  19. Women who are pregnant or lactating.
  20. Unable or unwilling to provide .
  21. Have had a tattoo or body piercing within 30 days prior to first study drug administration.

    BPSI Protocol Number: 2953 Sponsor Protocol Number: LEV-004/K Protocol Version Number: 1.0, Dated: Oct-14-2025 Levetiracetam 1500 mg coated granules in sachet formulations Fasting Conditions Page 22 of 51

  22. A participant who, in the opinion of the investigator or designee, is considered unsuitable or unlikely to comply with the study protocol for any reason.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Levetiracetam 1500 mg

    Levetiracetam 1500 mg coated granules, single oral dose

    Drug: Levetiracetam 1500 mg

  • Active comparator
    Keppra 750 mg

    Keppra 750 mg film-coated tablets, single oral dose of two tablets

    Drug: Keppra® 750 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence between Levetiracetam Desitin 1500 mg coated granules and Keppra

    Bioequivalence is concluded under fasting conditions if the 90% confidence interval for the Test/Reference ratios of geometric means for AUCt and Cmax are contained within the ICH-defined acceptance range of 80-125% for levetiracetam

    Time frame: From enrollment to the end of clinical phase at 2 weeks

  2. AUC

    Area under Curve

    Time frame: From enrollment to the end of the study at 1 week

07

Study locations

1 site
  • Biopharma Services Inc.
    Toronto, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: No — internal confidential data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Jan 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Feb 6, 2026
StartActual
Dec 17, 2025
Primary completionActual
Jan 5, 2026
CompletionActual
Jan 5, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07393022
Lead sponsor
Desitin Arzneimittel GmbH
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Dec 17, 2025
Primary completion
Jan 5, 2026
Completion
Jan 5, 2026
Last update
Feb 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion